RxDoctor Payments Data

Brian Helmetag, OD

Optometrist · Philadelphia, PANPI 1891439261

Payments from drug & device makers

$734in general payments, 2019–2025

Across 23 payments — averaging $31.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$285
  • Harrow Eye, LLC$117
  • Sun Pharmaceutical Industries Inc.$117
  • Oyster Point Pharma, Inc.$70
  • AbbVie$50
  • Tarsus Pharmaceuticals, Inc.$35
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$734 in reported general payments places this provider in the 45th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$13,661
Medicare patients
102
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast47$32,848
RestasisCyclosporine28$16,807
CombiganBrimonidine Tartrate/Timolol40$10,138
Restasis MultidoseCyclosporine11$6,707
LumiganBimatoprost12$5,901
Azelastine Hcl397$4,600
Latanoprost415$3,761
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$3,029
Tobramycin-DexamethasoneTobramycin/Dexamethasone52$2,098
Dorzolamide-TimololDorzolamide/Timolol/Pf20$1,876
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat93$1,031
Prednisolone Acetate20$706
Brimonidine Tartrate32$624
Ketorolac Tromethamine13$324
Timolol Maleate20$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Restasis Multidose, Lumigan$50$39,55391 claims
Bausch & Lomb Americas Inc.Xiidra$285$32,84847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →